Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of ATGC-110 for Glabellar Frown Lines
NCT04281095Phase 2Completed
- Sponsor
- ATGC
- Start
- Nov 2019
- Primary completion
- Apr 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of Botaluma in glabellar lines, sponsored by ATGC. Started Nov 2019; status: completed.
02
Drugs
Botaluma
03
Conditions
glabellar lines
Beyond the preview
Go deeper on NCT04281095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04281095.